question time

Hughjas, gm, jevalent or anyone else for that matter

I have quickly gone through threads, agree lots of informative research/discussion/posts

so let me get this straight

Polynovo

1. one area of application Topical Negative Pressure (TNP) wound dressing.

"PolyNovo is preparing a 510(k) regulatory submission for marketing approval in this application. PolyNovo is in on-going discussions with several potential distribution partners in relation to the TNP wound dressing product."

so we are preparing to file 510 with the yanks and going by threads, company said the time taken to complete this is usually 5-6 months

and then this......

"From the release when Dr David McQuillan joined the CZD Board

In 2000, Dr McQuillan joined LifeCell Corporation as the Vice-President for Research and Development (R &
D). He led LifeCell’s development R & D team focusing on the creation of market-leading products for
reconstructive and plastic surgery applications. Following marketing approval in 2008 for its new
reconstructive tissue matrix StratticeTM, LifeCell was acquired by KCI for US$1.8 Billion. Following the
acquisition, Dr McQuillan became the Senior Vice President of the Advanced Research and Technology unit at
KCI. Dr McQuillan left KCI in 2011, after it was acquired by a private consortium for US$6.7 Billion.

Dr McQuillan with his network will and has probably already served CZD well.".......


So I take it a similar company with similar product line was taken over by KCI for $1.8 BILLION after securing just the Marketing Approval, which is the 510k stuff that we are going to file in the current qtr?

and that is not even FDA approval......$1.8 billion, is that right?

and you guys reckon one of the partners we are talking to is KCI.


2. going by preso Pg 11, another area of application Surgical Wounds BTM is also going through 510k application, whats the potential of that?

3. full thickness wounds trial results expected Oct

4. whole lot other applications in talks with other partners

any thoughts welcome.

AOD seems to be just sideshow atm, but the media made a circus full by the looks & the ASADA report next week. What's likely to happen here? just apology?

"Over the next six months Metabolic’s focus will be to license or partner AOD9604 to human and veterinary pharmaceutical companies for the treatment and repair of obesity, bone, muscle and cartilage related disorders. At the expiry of that six month period and depending on the outcomes achieved, the Calzada Board and Management will review its ongoing commitment to the Metabolic’ business, including whether it may be separated as an entity in its own right."